[Role of insufficient hormone production in development of osteopenia in consequence of physical loads defficiency].

Experiments with rats deprived of support loading on hind limbs by tail-suspension showed that injection of hormones participating in bone metabolism impeded the development of tibial spongy osteopenia; also, normalization of longitudinal bone growth was observed in several cases. Investigations were aimed to evaluate the effectiveness of growth hormone, sex hormones, thyreoid hormones, calcitonin, CNS stimulating ephedrine and strychnine, and graded support loads. The best results were obtained after injection of calcitonin combined with sinestrol (synthetic analog of estradiol) and graded support loads which acted as initiators and amplifiers of hormonal effects. The combination of calcitonin, sinestrol and support loads prevented osteopenia and provided the normal bone growth in length during rat's suspension.

[Functional state of calcitonin-producing cells of the female rats' thyroid as a result of experimental osteopenia therapy by graduated support loading combined with oestrogens and calcitonin injection].

Effects of graduated (2-hr.) support loading, synestrol and myocalcic on the thyroid C-cells was evaluated with the immunocytochemistry and cytomorphometry techniques. Graduated support loading was shown to partially recondition degraded functioning of C-cells. Synestrol injection suppressed the stimulating effect of support loading; myocalcic had a little effect on the C-cell activity. Simultaneous injection of two substances cancelled out the stimulating effect of support loading.

Labial adhesions presenting as urinary incontinence in postmenopausal women.

Most discussion on labial adhesions is about the pediatric group. A case is presented of a postmenopausal woman whose main complaint was urinary incontinence. Etiology, symptoms, signs, and diagnosis are discussed. Guidelines for treatment and prevention are proposed. Because the number of postmenopausal women is steadily increasing, it is important to draw attention to this condition.

[Postoperative hormone therapy of breast cancer (analysis of overall survival)]. / Posleoperatsionnaia gormonoterapiia raka molochnoi zhelezy (analiz obshchei vyzhivaemosti)

A third series of randomized evaluation of postoperative (adjuvant) hormone therapy (tamoxifen, sinestrol and orimeten) was carried out in breast cancer patients. The study group involved 1.332 reproductive and postmenopausal females with stage I-III tumors. The investigation established quite a range of 10-year survival evidence versus stage and reproductive status; however, no significant differences were recorded in either of the groups. Untoward side-effects were more frequent when treating with diethyl-stilbestrol (over 30%) than with tamoxifen (3.5%). No significant differences were registered in five-year total and recurrence-free survival in the treatment with orimeten or tamoxifen.

[Diagnosis and therapeutic correction of changes in the cardiovascular system of patients with prostatic cancer treated with estrogens]. / Diagnostika i lechebnaia korrektsiia izmenenii serdechno-sosudistoi sistemy u bol'nykh rakom predstatel'noi zhelezy na fone éstrogeno- terapii.

Estrogen-related cardiovascular dysfunction was noted in 23 out of 30 patients with prostatic cancer (PC). Coronary subjects with PC suffered from cardiac pain evident on ECG necessitating correction by effective doses of coronary active drugs. PC patients with essential hypertension exhibited frequent headache, progressive edema of the legs, drastic hypertensive reactions. It is held that estrogen therapy for prostatic cancer should be preceded and monitored by therapeutic evaluation responsible for optimal conditions to prevent and early diagnose cardiovascular complications.

Endocrine effects of oestrogen treatment in patients with prostatic cancer.

In 36 men with prostatic cancer, the following findings were obtained: intravenous administration of 12.0 g diethylstilboestrol diphosphate (DSDP) induced a relatively slight decrease of the LH plasma level from 22.7 +/- 11.8 to 7.7 +/- 3.6 mIU/ml (34%), whereas the total testosterone plasma level decreased from 435.3 +/- 187.8 to 29.9 +/- 16.4 ng/100 ml (6.7%) suggesting a direct inhibitory effect of the oestrogen on testicular testosterone secretion. The apparently free, biologically active testosterone plasma level even decreased from 6.2 +/- 3.7 to 0.21 +/- 0.16 ng/100 ml (3.4%), due to the oestrogen-induced increase of the concentration of testosterone-binding beta-globulin (from 9.6 +/- 4.4 to 20.6 +/- 10.7-10(-8) M). 3--7 days after additional orchidectomy plus subcutaneous implantation of 100 mg dienoestrol diacetate a further decrease of the apparently free testosterone plasma level from 0.21 +/- 0.16 to 0.14 +/- 0.07 ng/100 ml was found. In contrast, 6 weeks after orchidectomy without oestrogen implantation a significant increase of th- apparently free testosterone plasma level -rom 0.21 %/- 0.16 to 0.34 +/- 0.15 ng/100 ml was observed (p less than 0.01). In view of these findings the biologically active free testosterone plasma level appears to be even more suppressed by intravenous administration of high DSDP than by orchidectomy. The most effective suppression of apparently free testosterone was achieved, however, by oestrogen treatment combined with orchidectomy.

Hormonal replacement therapy in patients after cervical cancer treatment.

Study was made of 120 patients after surgery and/or radiotherapy for Stage I and II cervical cancer. A group of 80 patients received hormonal replacement treatment: 40 patients were treated with Trisequens (Novo)--(group T), and 40 with sequentially Dienestrol and Chlormadinon (Polfa)--(group D-Ch); the remaining 40 patients received no hormone therapy (control group). For all groups the observation time was at least 5 years. In both hormonally treated groups, evaluation was made of the effect of hormonal treatment on quality of life (intensity of climacteric complaints, postradiological changes, etc.) and on the results on oncological treatment, with special consideration of the incidence of cancer recurrence. The hormonal treatment enabled control of most climacteric symptoms, without any serious side-effects as well relieved rectal, bladder, and vaginal postradiological complications. In the whole material (120 patients) the results of oncological treatment were satisfactory. In the hormonally treated group and in controls, 5-year survival without cancer symptoms was found in 80 and 65% of cases, respectively (insignificant difference). In the hormonally treated group and in the controls, the incidence of cancer recurrences amounted to 20 and 32%, respectively (insignificant difference). The promising results of the present studies suggest the need for their continuation to aim of improving of quality of life the women treated in premenopausal age for cervical cancer.

[Action of tamoxifen on the sex organs of guinea pigs]. / Deistvie tamoksifena na polovye organy morskikh svinok.

Long-term administration of tamoxifen (3-5 months) in a dose of 0.4 mg/kg to guinea-pigs with estrogen-induced benign uterine tumors had no toxic effects on the animals. Tamoxifen caused no noticeable changes in the ovarian mass, however, 40% of the guinea-pigs manifested ovulation suppression. Analysis of vaginal smears showed that most animals were in the stage of unestrus. Long-term administration of tamoxifen alone did not lead to the development of uterine polyps or tumors. Tamoxifen alone or combined with synestrol provoked a marked decrease in the level of free cytoplasmic estrogen and glucocorticoid receptors in the uterines of the guinea-pigs. In the course of long-term administration of tamoxifen alone, a tendency towards progesterone receptor decrease in the uterus was demonstrated.